Longterm visual field follow-up of glaucoma patients treated with beta-blockers

In a prospective, randomized, double-masked study, 44 patients with primary open-angle glaucoma were treated either with 0.5% betaxolol or 0.5% timolol in both eyes twice daily. Twenty-nine patients could be followed up for 48 months. Seventeen of these patients were treated with betaxolol and 12 with timolol. Each examination included visual field measurements with an Octopus automated perimeter 201 (Program G1), intraocular pressure measurement, funduscopy, as well as pulse and arterial blood pressure measurements. Both drugs lowered in the intraocular pressure. This reduction was slightly but not statistically significantly higher in the timolol-treated group. However, the visual fields improved more in the betaxolol group. Patients treated with betaxolol had significantly smaller averaged mean defects (p < 0.05) and higher averaged mean sensitivities (p < 0.05, Wilcoxon rank score text) than did timolol-treated patients at months 3, 6, 12, and 18. Thereafter, the difference between the two groups was not statistically significant in this relatively small sample size. For betaxolol patients the cumulative area-under-the-curve analysis for the worse eye yielded significantly larger mean sensitivities beyond month 12 (exception: month 30; p < 0.05) and significantly smaller mean defects beyond month 6 (p < 0.05).